Which Small-Cap Value ETF Is Better: State Street's SLYV or iShares' ISCV?

ISCV offers a lower 0.06% expense ratio versus SLYV’s 0.15%, while matching its roughly 2% dividend yield and showing a smaller 5-year drawdown of -25.34% versus -28.67%. ISCV also has broader diversification with over 1,000 holdings versus SLYV’s roughly 460, though SLYV has the stronger 1-year return at 45.1% versus 36.1%. The piece is mostly a comparative ETF analysis, with modest investor relevance rather than a major market catalyst.

Analysis

The main implication is not “cheaper index fund wins,” but that ISCV’s broader, less filtered basket is a cleaner expression of a small-cap value rebound if rates stay sticky and cyclical breadth improves. Its higher breadth reduces single-name idiosyncrasy and should matter most in a regime where the market starts rewarding book/earnings mean reversion over balance-sheet quality. SLYV’s profitability screen likely improves downside behavior in true credit stress, but it also biases the fund toward higher-quality traps that can lag in sharp value rallies.

Second-order, the names embedded in ISCV tilt toward capital-intensity and commodity-adjacent cyclicals, which makes the ETF more sensitive to curve steepening and a better beneficiary if real yields drift lower over the next 3-6 months. That said, the presence of higher-velocity businesses like MRNA and MTCH alongside cyclicals means the basket is not a pure macro bet; it is a mixed factor sleeve where idiosyncratic catalysts can overwhelm the style exposure. The market is likely underappreciating how much the lower fee compounds over multi-year holding periods when the return differential is otherwise small.

The contrarian read is that SLYV’s recent relative strength may be partly a quality premium masquerading as better “value” exposure, especially after a period where profitability screens were rewarded. If macro growth rolls over or credit spreads widen, ISCV’s broader, deeper-value exposure should see higher dispersion but also more upside convexity on easing financial conditions. The key risk is that small-cap value leadership fails to broaden beyond a handful of balance-sheet survivors, in which case SLYV’s screen is worth paying for.

Key Decisions for Investors

• Long ISCV / short SLYV for a 3-6 month mean-reversion trade if rates start falling or the Fed pivots dovish; target 3-5% relative outperformance for ISCV with tight risk controls if credit spreads stay contained.
• Use ISCV as the core small-cap value sleeve for a 1-3 year horizon; the 9 bps fee advantage compounds meaningfully, and the broader basket reduces single-factor disappointment risk versus a more concentrated competitor.
• If you want to express a risk-off view, rotate from ISCV into SLYV on any widening in high-yield spreads; SLYV’s profitability filter should hold up better in a late-cycle slowdown.
• Pair ISCV against IWM call overwriting rather than outright small-cap beta: the goal is to isolate value re-rating while reducing index-level noise if small-cap volatility persists.
• Watch CF/AA/EMN as early telltales for cyclical breadth; if those names stabilize while rates ease, add to ISCV on weakness and look for a 6-12 month rerating in deeper value exposure.